Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01471171 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: Aclidinium Bromide
DRUG: Placebo

Sponsor

AstraZeneca